A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies — StellaEarly Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.
Trial locations(1 site)
China
The First Affiliated Hospital，College of Medicine, Zhejiang University, Hangzhou, Zhejiang Last updated October 2020